Efficacy of N-acetylcysteine in phenotypic suppression of mouse models of niemann-pick disease, type C1

Human Molecular Genetics

Volumn 22, Issue 17, 2013, Pages 3508-3523

  Fu, Rao ^a   Wassif, Christopher A ^a   Yanjanin, Nicole M ^a   Watkins Chow, Dawn E ^b   Baxter, Laura L ^b   Incao, Art ^b   Liscum, Laura ^c   Sidhu, Rohini ^d   Firnkes, Sally ^d   Graham, Mark ^e   Ory, Daniel S ^d   Porter, Forbes D ^a   Pavan, William J ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA,5ALPHA,6BETA CHOLESTANETRIOL; 7 OXOCHOLESTEROL; ACETYLCYSTEINE; MIGLUSTAT; OXYSTEROL; UBIDECARENONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CHILD; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE COURSE; DRUG EFFICACY; DRUG SCREENING; EXPERIMENTAL MODEL; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENOME ANALYSIS; HUMAN; KNOCKOUT MOUSE; LIPID STORAGE; LIVER DISEASE; MALE; MONOTHERAPY; MOUSE; NEUROLOGIC DISEASE; NIEMANN PICK DISEASE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 84881600379     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt206     Document Type: Article

References (63)

1. Vanier, M.T. (2010) Niemann-Pick disease type C. Orphanet. J. Rare Dis., 5, 16.
2. Carstea, E.D., Morris, J.A., Coleman, K.G., Loftus, S.K., Zhang, D., Cummings, C., Gu, J., Rosenfeld, M.A., Pavan, W.J., Krizman, D.B. et al. (1997) Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science, 277, 228-231.
3. Naureckiene, S., Sleat, D.E., Lackland, H., Fensom, A., Vanier, M.T., Wattiaux, R., Jadot, M. and Lobel, P. (2000) Identification of HE1 as the second gene of Niemann-Pick C disease. Science, 290, 2298-2301.
4. Sleat, D.E., Wiseman, J.A., El-Banna, M., Price, S.M., Verot, L., Shen, M.M., Tint, G.S., Vanier, M.T., Walkley, S.U, Lobel, P. (2004) Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport. Proc. Natl Acad. Sci. USA, 101, 5886-5891.
5. Subramanian, K, Balch, W.E. (2008)NPC1/NPC2 function as a tag team duo to mobilize cholesterol. Proc. Natl Acad. Sci. USA, 105, 15223-15224.
6. Infante, R.E., Wang, M.L., Radhakrishnan, A., Kwon, H.J., Brown, M.S, Goldstein, J.L. (2008) NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes. Proc. Natl Acad. Sci. USA, 105, 15287-15292.
7. Rosenbaum, A.I, Maxfield, F.R. (2011) Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches. J. Neurochem., 116, 789-795.
8. Frolov, A., Zielinski, S.E., Crowley, J.R., Dudley-Rucker, N., Schaffer, J.E, Ory, D.S. (2003) NPC1 and NPC2 regulate cellular cholesterol homeostasis through generation of low density lipoprotein cholesterol-derived oxysterols. J. Biol. Chem., 278, 25517-25525.
9. Schedin, S., Sindelar, P.J., Pentchev, P., Brunk, U, Dallner, G. (1997) Peroxisomal impairment in Niemann-Pick type C disease. J. Biol. Chem., 272, 6245-6251.
10. Lloyd-Evans, E., Morgan, A.J., He, X., Smith, D.A., Elliot-Smith, E., Sillence, D.J., Churchill, G.C., Schuchman, E.H., Galione, A, Platt, F.M. (2008) Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med., 14, 1247-1255.
11. Shen, D., Wang, X., Li, X., Zhang, X., Yao, Z., Dibble, S., Dong, X.-P., Yu, T., Lieberman, A.P., Showalter, H.D. et al. (2012) Lipid storage disorders block lysosomal trafficking by inhibiting a TRP channel and lysosomal calcium release. Nat. Commun., 3, 731.
12. Griffin, L.D., Gong, W., Verot, L, Mellon, S.H. (2004) Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat. Med., 10, 704-711.
13. Baudry, M., Yao, Y., Simmons, D., Liu, J, Bi, X. (2003) Postnatal development of inflammation in a murine model of Niemann-Pick type C disease: immunohistochemical observations of microglia and astroglia. Exp. Neurol., 184, 887-903.
14. Wu, Y.-P., Mizukami, H., Matsuda, J., Saito, Y., Proia, R.L, Suzuki, K. (2005) Apoptosis accompanied by up-regulation of TNF-alpha death pathway genes in the brain of Niemann-Pick type C disease. Mol. Genet. Metab., 84, 9-17.
15. Klein, A., Maldonado, C., Vargas, L.M., Gonzalez, M., Robledo, F., Perez de Arce, K., Muñoz, F.J., Hetz, C., Alvarez, A.R, Zanlungo, S. (2011) Oxidative stress activates the c-Abl/p73 proapoptotic pathway in Niemann- Pick type C neurons. Neurobiol. Dis., 41, 209-218.
16. Fu, R., Yanjanin, N.M., Bianconi, S., Pavan, W.J, Porter, F.D. (2010) Oxidative stress in Niemann-Pick disease, type C. Mol. Genet. Metab., 101, 214-218.
17. Vázquez, M.C., Balboa, E., Alvarez, A.R, Zanlungo, S. (2012) Oxidative stress: a pathogenic mechanism for niemann-pick type C disease. Oxid. Med. Cell Longev., 2012, 205713.
18. Loftus, S.K., Morris, J.A., Carstea, E.D., Gu, J.Z., Cummings, C., Brown, A., Ellison, J., Ohno, K., Rosenfeld, M.A., Tagle, D.A. et al. (1997) Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science, 277, 232-235.
19. Rimkunas, V.M., Graham, M.J., Crooke, R.M, Liscum, L. (2008) In vivo antisense oligonucleotide reduction of NPC1 expression as a novel mouse model for Niemann Pick type C- associated liver disease. Hepatology, 47, 1504-1512.
20. Võikar, V., Rauvala, H, Ikonen, E. (2002) Cognitive deficit and development of motor impairment in a mouse model of Niemann-Pick type C disease. Behav. Brain Res., 132, 1-10.
21. Pentchev, P.G., Boothe, A.D., Kruth, H.S., Weintroub, H., Stivers, J, Brady, R.O. (1984) A genetic storage disorder in BALB/C mice with a metabolic block in esterification of exogenous cholesterol. J. Biol. Chem., 259, 5784-5791.
22. Morris, M.D., Bhuvaneswaran, C., Shio, H, Fowler, S. (1982) Lysosome lipid storage disorder in NCTR-BALB/c mice. I. Description of the disease and genetics. Am. J. Pathol., 108, 140-149.
23. Xie, C., Burns, D.K., Turley, S.D, Dietschy, J.M. (2000) Cholesterol is sequestered in the brains of mice with Niemann-Pick type C disease but turnover is increased. J. Neuropathol. Exp. Neurol., 59, 1106-1117.
24. Zervas, M., Dobrenis, K, Walkley, S.U. (2001) Neurons in Niemann- Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J. Neuropathol. Exp. Neurol., 60, 49-64.
25. Dean, O., Giorlando, F, Berk, M.(2011) N-Acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J. Psychiatry Neurosci., 36, 78-86.
26. Parasassi, T., Brunelli, R., Costa, G., De Spirito, M., Krasnowska, E., Lundeberg, T., Pittaluga, E, Ursini, F. (2010) Thiol redox transitions in cell signaling: a lesson from N-acetylcysteine. Sci. World J., 10, 1192-1202. 27. Kanter, M.Z. (2006) Comparison of oral and i.v. acetylcysteine in the treatment of acetaminophen poisoning. Am. J. Health Syst. Pharm., 63, 1821-1827.
27. Kanter, M.Z. (2006) Comparison of oral and i.v. acetylcysteine in the treatment of acetaminophen poisoning. Am. J. Health Syst. Pharm., 63, 1821-1827.
28. Millea, P.J. (2009) N-acetylcysteine: multiple clinical applications. Am. Fam. Physician, 80, 265-269.
29. Cenedella, R.J. (2009) Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids, 44, 477-487.
30. Koh, C.H.V., Whiteman, M., Li, Q.-X., Halliwell, B., Jenner, A.M., Wong, B.S., Laughton, K.M., Wenk, M., Masters, C.L., Beart, P.M. et al. (2006) Chronic exposure to U18666A is associated with oxidative stress in cultured murine cortical neurons. J. Neurochem., 98, 1278-1289.
31. Zampieri, S., Mellon, S.H., Butters, T.D., Nevyjel, M., Covey, D.F., Bembi, B, Dardis, A. (2009) Oxidative stress in NPC1 deficient cells: protective effect of allopregnanolone. J. Cell. Mol. Med., 13, 3786-3796.
32. Marí, M., Caballero, F., Colell, A., Morales, A., Caballeria, J., Fernandez, A., Enrich, C., Fernandez-Checa, J.C, García-Ruiz, C. (2006) Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab., 4, 185-198.
33. Zhang, J.R., Coleman, T., Langmade, S.J., Scherrer, D.E., Lane, L., Lanier, M.H., Feng, C., Sands, M.S., Schaffer, J.E., Semenkovich, C.F. et al. (2008) Niemann-Pick C1 protects against atherosclerosis in mice via regulation of macrophage intracellular cholesterol trafficking. J. Clin. Invest., 118, 2281-2290.
34. Cologna, S.M., Jiang, X.-S., Backlund, P.S., Cluzeau, C.V.M., Dail, M.K., Yanjanin, N.M., Siebel, S., Toth, C.L., Jun, H.-S., Wassif, C.A. et al. (2012) Quantitative proteomic analysis of niemann-pick disease, type c1 cerebellum identifies protein biomarkers and provides pathological insight. PLoS ONE, 7, e47845.
35. Ribas, G.S., Pires, R., Coelho, J.C., Rodrigues, D., Mescka, C.P., Vanzin, C.S., Biancini, G.B., Negretto, G., Wayhs, C.A.Y., Wajner, M. et al. (2012) Oxidative stress in Niemann-Pick type C patients: a protective role of N-butyl-deoxynojirimycin therapy. Int. J. Dev. Neurosci., 10.1016/ j.ijdevneu.2012.07.002.
36. Jiang, X., Sidhu, R., Porter, F.D., Yanjanin, N.M., Speak, A.O., Vruchte,te, D.T., Platt, F.M., Fujiwara, H., Scherrer, D.E., Zhang, J. et al. (2011) A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann- Pick C1 disease from human plasma. J. Lipid Res., 52, 1435-1445.
37. Porter, F.D., Scherrer, D.E., Lanier, M.H., Langmade, S.J., Molugu, V., Gale, S.E., Olzeski, D., Sidhu, R., Dietzen, D.J., Fu, R. et al. (2010) Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci. Transl. Med., 2, 56ra81.
38. Cluzeau, C.V.M., Watkins-Chow, D.E., Fu, R., Borate, B., Yanjanin, N., Dail, M.K., Davidson, C.D., Walkley, S.U., Ory, D.S., Wassif, C.A. et al. (2012) Microarray expression analysis and identification of serum biomarkers forNiemann-Pick disease, type C1.Hum.Mol. Genet., 10.1093/ hmg/dds193.
39. Alam, M.S., Getz, M., Safeukui, I., Yi, S., Tamez, P., Shin, J., Velázquez, P, Haldar, K. (2012)Genomicexpression analyses reveal lysosomal, innate immunity proteins, as disease correlates in murine models of a lysosomal storage disorder. PLoS ONE, 7, e48273.
40. Reddy, J.V., Ganley, I.G, Pfeffer, S.R. (2006) Clues to neuro-degeneration in Niemann-Pick type C disease from global gene expression profiling. PLoS ONE, 1, e19.
41. Liao, G., Wen, Z., Irizarry, K., Huang, Y., Mitsouras, K., Darmani, M., Leon, T., Shi, L, Bi, X. (2010) Abnormal gene expression in cerebellum of Npc1-/- mice during postnatal development. Brain Res., 1325, 128-140.
42. Lopez, M.E., Klein, A.D., Hong, J., Dimbil, U.J, Scott, M.P. (2012) Neuronal and epithelial cell rescue resolves chronic systemic inflammation in the lipid storage disorder Niemann-Pick C. Hum. Mol. Genet., 21, 2946-2960.
43. Vázquez, M.C., del Pozo, T., Robledo, F.A., Carrasco, G., Pavez, L., Olivares, F., González, M, Zanlungo, S. (2011) Alteration of gene expression profile in Niemann-Pick type C mice correlates with tissue damage and oxidative stress. PLoS ONE, 6, e28777.
44. Davidson, C.D., Ali, N.F., Micsenyi, M.C., Stephney, G., Renault, S., Dobrenis, K., Ory, D.S., Vanier, M.T, Walkley, S.U. (2009) Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS ONE, 4, e6951.
45. Liu, B., Turley, S.D., Burns, D.K., Miller, A.M., Repa, J.J, Dietschy, J.M. (2009) Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse. Proc. Natl Acad. Sci. USA, 106, 2377-2382.
46. Liu, B., Ramirez, C.M., Miller, A.M., Repa, J.J., Turley, S.D, Dietschy, J.M. (2010) Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid. J. Lipid Res., 51, 933-944.
47. Ramirez, C.M., Liu, B., Taylor, A.M., Repa, J.J., Burns, D.K., Weinberg, A.G., Turley, S.D, Dietschy, J.M. (2010) Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick typeC1mouse and markedly prolongs life. Pediatr. Res., 68, 309-315.
48. Patterson, M.C., Vecchio, D., Jacklin, E., Abel, L., Chadha-Boreham, H., Luzy, C., Giorgino, R, Wraith, J.E. (2010) Long-term miglustat therapy in children with Niemann-Pick disease type C. J. Child Neurol., 25, 300-305.
49. Zhang, M., Strnatka, D., Donohue, C., Hallows, J.L., Vincent, I, Erickson, R.P. (2008) Astrocyte-onlyNpc1reduces neuronal cholesterol and triples life span of Npc1-/- mice. J. Neurosci. Res., 86, 2848-2856.
50. Tucker, S., Ahl, M., Bush, A., Westaway, D., Huang, X, Rogers, J.T. (2005) Pilot study of the reducing effect on amyloidosis in vivo by threeFDA pre-approved drugs via the Alzheimer's APP 5' untranslated region. Curr. Alzheimer Res., 2, 249-254.
51. Adair, J.C., Knoefel, J.E, Morgan, N. (2001) Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology, 57, 1515-1517.
52. Clark, J., Clore, E.L., Zheng, K., Adame, A., Masliah, E, Simon, D.K. (2010) Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. PLoS ONE, 5, e12333.
53. Muñoz, A.M., Rey, P., Soto-Otero, R., Guerra, M.J, Labandeira-Garcia, J.L. (2004) Systemic administration of N-acetylcysteine protects dopaminergic neurons against 6-hydroxydopamine-induced degeneration. J. Neurosci. Res., 76, 551-562.
54. Cuzzocrea, S., Mazzon, E., Costantino, G., Serraino, I., Dugo, L., Calabro, G., Cucinotta, G., De Sarro, A, Caputi, A.P. (2000) Beneficial effects of N-acetylcysteine on ischaemic brain injury. Br. J. Pharmacol., 130, 1219-1226.
55. Koch, A, Trautwein, C. (2010) N-acetylcysteine on its way to a broader application in patients with acute liver failure. Hepatology, 51, 338-340.
56. Beloqui, O., Prieto, J., Suárez, M., Gil, B., Qian, C.H., García,N, Civeira, M.P. (1993) N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J. Interferon Res., 13, 279-282.
57. Farr, S.A., Poon, H.F., Dogrukol-Ak, D., Drake, J., Banks, W.A., Eyerman, E., Butterfield, D.A, Morley, J.E. (2003) The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J. Neurochem., 84, 1173-1183.
58. Yan, C.Y, Greene, L.A. (1998) Prevention of PC12 cell death by N-acetylcysteine requires activation of the Ras pathway. J. Neurosci., 18, 4042-4049.
59. Patterson, M.C., Mengel, E., Wijburg, F.A., Muller, A., Schwierin, B., Drevon, H., Vanier, M.T, Pineda, M. (2013) Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J. Rare Dis., 8, 12.
60. Wassif, C.A., Krakowiak, P.A., Wright, B.S., Gewandter, J.S., Sterner, A.L., Javitt, N., Yergey, A.L, Porter, F.D. (2005) Residual cholesterol synthesis and simvastatin induction of cholesterol synthesis in Smith- Lemli-Opitz syndrome fibroblasts. Mol. Genet. Metab., 85, 96-107.
61. Benjamini, Y, Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Royal Stat. Soc. B, 57, 289-300.
62. Yanjanin, N.M., Vélez, J.I., Gropman, A., King, K., Bianconi, S.E., Conley, S.K., Brewer, C.C., Solomon, B., Pavan, W.J., Arcos-Burgos, M. et al. (2010) Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 153B, 132-140.
63. Yang, J.-S., Nam, H.-J., Seo, M., Han, S.K., Choi, Y., Nam, H.G., Lee, S.-J, Kim, S. (2011) OASIS: online application for the survival analysis of lifespan assays performed in aging research. PLoS ONE, 6, e23525.